Pernix Therapeutics Holdings has reported a net loss of $270,342, or $0.01 per share, for the third quarter ended 30 September 2012 compared to a net income of $1.99m, or $0.08 per share, for thesame period in 2011. Net sales for the ...
Pernix Therapeutics Holdings has launched Omeclamox-Pak, a ten-day therapy, to eradicate Helicobacter pylori (H. pylori) in adult patients. Omeclamox-Pak is composed of omeprazole delayed-release capsules (20mg), clarithromycin tablets ...
Tags: Omeclamox-Pak, H.pylori, ten-day therapy
Pernix Therapeutics, a specialty pharmaceutical company, has announced the availability of Omeclamox-Pak to treat Helicobacter pylori (H. pylori) infection and duodenal ulcer disease (active or one-year history) to eradicate H. pylori in ...
Tags: Oral Therapy, Omeclamox-Pak, H.pylori